Gitnux/Report 2026

Cpap Industry Statistics

Adherence is the battleground for US CPAP care right now, with only 35 to 50% still using CPAP after 3 months and mask fit problems driving 40% of early discontinuations in the first month. Telemonitoring flips that outcome, lifting more patients into the clinically meaningful 4+ hours per night, while Medicare spends about $1,200 per beneficiary each year and the global CPAP devices market is projected to climb from USD 4.29 billion in 2023 at an 8.1% CAGR toward roughly USD 7 by 2030.
286Statistics
56Sources
12Sections
1Visuals
46mRead
November 11, 2026Updated
Cpap Industry Statistics
Catherine WuWritten by Catherine Wu·Edited by Ryan Townsend·Fact-checked by Olivia Thornton
Published ·Updated
How this report is researched
01Editorial Scope

Gitnux editors write the brief first: the topic, the inclusion rules, and the frame for what belongs.

02Source Research

Agents search the published record and log every extracted figure back to the passage it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 31 days

01 Industry overview

The cpap industry at a glance

The global CPAP devices market is estimated at $1.97 billion in 2026, with North America accounting for 47.0% of 2025 revenue and connected home therapy supporting continued expansion.

$1.97B[49]
Global market size, 2026
4.88%[49]
Forecast CAGR, 2026–2035
47.0%[50]
North America share, 2025
$5.1B[1]
ResMed FY2025 revenue
Market size
The global CPAP devices market is estimated at $1.88 billion in 2025 and $1.97 billion in 2026. It is projected to reach $3.02 billion by 2035.[49]
Forecast & CAGR
The market is forecast to grow at a 4.88% compound annual growth rate from 2026 to 2035. Europe is projected to expand at a 5.5% CAGR through 2035 in one market estimate.[49][50]
Market share & regions
North America held 47.0% of global CPAP-device revenue in 2025, while Europe represented 24.0% in the same year. North America remains the leading regional market, supported by established diagnosis, home-care and reimbursement infrastructure.[50]
Segmentation
The market includes fixed-pressure CPAP, auto-adjusting CPAP and related masks and accessories. A BCC Research market overview reported one-pressure CPAP machine revenue of $424.2 million in 2024, with a 2018–2024 CAGR of 5.1%.
Key players & concentration
ResMed and Philips Respironics are the best-known global CPAP suppliers, alongside Fisher & Paykel Healthcare, React Health, Löwenstein Medical and BMC Medical. ResMed reported $5.1 billion in FY2025 revenue across devices, masks and other products, but public sources do not provide a reliable current CPAP-only concentration ratio.[1]
Pricing
In the United States, Medicare Part B covers eligible CPAP therapy after the deductible, with beneficiaries generally paying 20% of the Medicare-approved amount. Medicare rents a CPAP machine for 13 continuous months before ownership transfers to the beneficiary.[51]
Trends, drivers & challenges
Growth is being supported by rising diagnosis of obstructive sleep apnea, home-based therapy, auto-adjusting devices and cloud-connected adherence tools. Product safety and regulatory remediation remain major challenges: the FDA says the 2021 Philips recall affected 15 million devices worldwide, while Philips reported that more than 99% of actionable sleep-therapy registrations had been remediated by its latest update.[40][32]
Consumer behavior & competition
CPAP demand is concentrated in diagnosed obstructive-sleep-apnea patients using therapy at home, with adherence and replacement supplies central to recurring sales. Medicare coverage requires a 12-week trial and continued documentation that therapy is helping; competition is increasingly based on comfort, mask fit, connected monitoring and digital coaching.[51]
Regulation
U.S. Medicare coverage requires a qualifying obstructive-sleep-apnea diagnosis, a 12-week trial and documented benefit for continued coverage. CMS reported a 12.5% improper-payment rate for CPAP in 2024 Medicare fee-for-service data, equal to a projected $146.1 million in improper payments.[51][52]
Latest news
The latest major industry development is Philips Respironics’ ongoing recall remediation and market-restoration program. Philips stated that new U.S. CPAP and BiPAP sales will resume only after relevant regulatory requirements are met, while the FDA posted a Class I recall in 2025 for certain reworked DreamStation Auto CPAP and Auto BiPAP devices affected by programming errors.[40]

02 Ranking

Top 5 Companies in the Cpap Industry

The leading companies in the cpap industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 11, 2026 · Next review December 11, 2026

Verdict

Fisher & Paykel Healthcare leads Gitnux's 2026 cpap ranking with an Overall score of 9.9, with 13% Homecare revenue growth to $739.9 million. ResMed is the highest-ranked connected therapy software provider at 9.5, with $5.15 billion fiscal-2025 total revenue, up 10% year over year.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in OSA masks and accessories

    Fisher & Paykel Healthcare

    NZ

    Ranked #1 · 9.9 · OSA masks and accessories

    Why we picked it: It reports Homecare growth and operates in OSA mask and home respiratory support, including humidification.

    See in ranking ↓Visit fphcare.com ↗

  2. Leader in sleep connected therapy software

    ResMed

    US

    Ranked #2 · 9.5 · Sleep connected therapy software

    Why we picked it: It spans devices, masks and masks-and-other revenue categories, with connected platforms used at scale.

    See in ranking ↓Visit resmed.com ↗

  3. Leader in home PAP devices

    React Health

    US

    Ranked #3 · 8.9 · Home PAP devices

    Why we picked it: It focuses on CPAP/APAP devices and masks, targeting home PAP therapy through named product lines.

    See in ranking ↓Visit reacthealth.com ↗

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 5 companies in the cpap industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Fisher & Paykel Healthcare

OSA masks and accessories · NZ

9.9
2

ResMed

Sleep connected therapy software · US

9.5
3

React Health

Home PAP devices · US

8.9
4

Löwenstein Medical

Home PAP devices · DE

8.5
5

Wellell

Home PAP devices · TW

7.0

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 11, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Catherine Wu. (2026, February 13). Top 5 companies in the cpap industry. In Cpap Industry Statistics. Gitnux. https://gitnux.org/cpap-industry-statistics/#top-companies

report visual · Comparison

Global CPAP device market share by region

Asia Pacific holds the largest share at 41.7%.

Asia Pacific41.7%
North America30.3%
Europe20.2%
Latin America4.5%
Middle East & Africa3.1%
source-verifiedreportsinsights.com

04 Statistics

Technology & Innovation

ResMed’s fiscal 2026 platform usage and AI tooling show how CPAP companies run product design and user support through connected ecosystems. A key scale point is 11.9 million myAir sign-ups by March 31, 2026.

AI in the cpap industry

  • ResMed embedded generative AI tools across research and development, operational support and product design in fiscal 2025.[1]
  • More than 12 million patients were registered on ResMed’s myAir platform in fiscal 2026, enabling personalized digital support for therapy users.[1]
  • More than 35 million patients used ResMed cloud-connected devices on AirView in fiscal 2026, supporting data-driven sleep and breathing care globally.[1]

Digital Transformation in the medical devices sector (sector benchmark)

  • Across medtech companies, 35% created value but failed to meet all digital-transformation targets in 2021.[2]
  • Across medtech companies, 36% achieved limited value and no sustainable change from digital transformation in 2021.[2]
  • Across medtech companies, 29% met or exceeded their digital-transformation targets with sustainable change in 2021, according to BCG’s global survey.[2]
  • Across medtech and IVD professionals worldwide, 87% said their company had implemented or planned to implement AI or digital solutions in regulatory or quality-management systems in 2020.[3]
  • Across medtech manufacturing executives, 64% highly prioritized digitizing manufacturing in a 2022 survey.[4]
  • Across medtech and IVD professionals worldwide, 89% said their company had implemented or planned to implement AI or digital solutions in its product range in 2020.[3]

Technology Adoption in the medical devices sector (sector benchmark)

  • Among emerging medtech companies, 38% had adopted clinical-trial-management systems, compared with 72% of enterprise and global companies in the 2025 benchmark.[5]
  • Across healthcare industrial-ecosystem SMEs in Europe, 8.6% already used remote patient-monitoring technologies in 2023.[6]
  • Across healthcare industrial-ecosystem SMEs in Europe, 13.7% already used artificial intelligence in 2023.[6]
  • Across healthcare industrial-ecosystem SMEs in Europe, 31.0% already used cloud technologies in 2023.[6]
  • Among emerging medtech companies, 62% had adopted electronic trial-master-file systems, compared with 89% of enterprise and global companies in the 2025 benchmark.[5]
  • Across healthcare industrial-ecosystem SMEs in Europe, 17.3% already used robotics in 2023.[6]

Cloud Computing in the medical devices sector (sector benchmark)

  • Across surveyed medtech organizations, 31% managed all postmarket-surveillance processes with cloud-based technology in 2025.[5]
  • Across medical-device manufacturing respondents in the global Industry Cloud Study, 21% reported that 75%–100% of infrastructure was in the cloud in 2022.[7]
  • Across medical-device manufacturing respondents in the global Industry Cloud Study, 66% reported that 50%–74% of infrastructure was in the cloud in 2022.[7]
  • Across surveyed medtech organizations, 33% reported reliable enterprise-wide use of cloud-based technologies in 2025.[5]

Big Data in the medical devices sector (sector benchmark)

  • Across medtech and biopharma companies surveyed in 2018, 67% of medtech firms invested in data analytics for reporting.[8]
  • 49% of medtech companies reported struggling with untimely data in Model N’s 2025 survey of industry leaders.[9]
  • 80% of medtech companies planned to invest in infrastructure, cloud enablement, tech-architecture modernization, and AI and big data, based on a 2021 global survey.[2]
  • 66.7% of medical device executives identified intelligent data analytics as a major theme for growth opportunities, according to an industry survey cited by Siemens.[10]
  • Across healthcare industrial-ecosystem SMEs in Europe, 15.3% had adopted big data and related data analytics in 2023.[6]
  • 15.3% of SMEs in Europe’s healthcare industrial ecosystem had adopted big data and related data analytics, according to the 2023 EMI survey.[6]

IoT in the medical devices sector (sector benchmark)

  • Among European healthcare industrial-ecosystem SMEs already using IoT, 22.3% used energy-saving devices such as smart lighting, HVAC or elevators in 2023.[6]
  • Among healthcare and medical-device IoT respondents, 9% had deployed between 10,001 and 100,000 connected devices in 2023.[11]
  • Among healthcare and medical-device IoT respondents, 84% planned to increase their connected-device estate in 2023.[12]
  • Across healthcare industrial-ecosystem SMEs in Europe, 20.4% already used Internet of Things technologies in 2023.[6]
  • Among European healthcare industrial-ecosystem SMEs already using IoT, 21.4% used predictive maintenance for production assets in 2023.[6]

05 Statistics

Data & Analytics

CPAP analytics appears as adherence measurement, telemonitoring outcomes, and API-driven ecosystem throughput. ResMed reports 475 or more API calls per second generated by integrators in its ecosystem as of March 31, 2026.

Business intelligence in the cpap industry

  • 34 million or more cloud-connectable devices were in ResMed’s ecosystem as of March 31, 2026.[1]
  • 1.5 million or more myAir inquiries were handled by ResMed’s Dawn generative-AI assistant in fiscal 2026.[1]
  • 475 or more API calls per second were generated by integrators in ResMed’s ecosystem as of March 31, 2026.[1]
  • 36 million or more patients were in ResMed AirView as of March 31, 2026.[1]
  • 28 billion or more nights of data were used to build ResMed’s digital ecosystem in fiscal 2026.[1]
  • 11.9 million or more patients were signed up to ResMed myAir as of March 31, 2026.[1]

Data analytics in the cpap industry

  • 64% of patients in the multimodal telemonitoring group met the greater-than-four-hours-on-70%-of-nights adherence threshold after six months.[13]
  • 49.9% of patients in ResMed’s AirView analysis used automatic positive-airway-pressure therapy.[1]
  • 9.2% of patients in ResMed’s AirView analysis used bilevel therapy.[1]
  • 40.9% of patients in ResMed’s AirView analysis used CPAP therapy.[1]
  • 87% was the adherence rate reported for CPAP users combining remote monitoring with self-monitoring in ResMed’s data analysis.[14]
  • 2.6 million or more U.S. sleep-disordered-breathing patients were included in ResMed’s AirView big-data adherence analysis.[1]

Data Quality in the medical devices sector (sector benchmark)

  • 51% of medical-device companies still managed postmarket-surveillance processes and data manually or partially manually in the 2025 benchmark survey.[5]
  • 45.9% of healthcare-sector business partners identified data quality as a major challenge in managing digital product information in the 2021 survey.[15]
  • 56% of medical-device companies used non-validated general-purpose tools for clinical data collection in the 2024 MedTech industry survey.[16]
  • 60% of medical-device professionals using literature-review software reported data traceability, compared with 4% using spreadsheets, in a global survey; survey year not stated.[17]
  • 73% of medical-device professionals using literature-review software trusted their data quality, compared with 38% using spreadsheets, in a global survey; survey year not stated.[17]

Data Governance in the medical devices sector (sector benchmark)

  • More than 72% of healthcare-sector business partners had not established a product-master-data system reflecting data governance in the 2021 survey.[15]
  • 62.3% of healthcare-sector business partners identified creating a central data master as a single source of truth as the greatest digital-product-information challenge in 2021.[15]
  • 31.4% of healthcare-sector business partners had a digital-asset-management system for storing images and product data sheets in the 2021 survey.[15]
  • More than 30% of healthcare-sector business partners had no clear formal data-governance guidelines in the 2021 survey.[15]

KPIs in the cpap industry

  • 4.8 hours was average daily CPAP use at 90 days in the Tele-OSA combined education-and-telemonitoring group.[18]
  • 4.0 hours was average daily CPAP use at 90 days in the Tele-OSA education group.[18]
  • 68.5% was the clinic show rate for patients receiving telemedicine education in the Tele-OSA trial.[18]
  • 26 L/min was the usual-care group’s median 95th-percentile leak rate after one year in the same trial.[19]
  • 3.8 hours was average daily CPAP use at 90 days in the Tele-OSA usual-care group.[18]
  • 4.4 hours was average daily CPAP use at 90 days in the Tele-OSA telemonitoring group.[18]

06 Statistics

Strategy & Growth

Strategy details link devices, masks, and homecare software to reported revenue mixes and product launches. ResMed also reports $641.4 million Residential Care Software revenue in fiscal 2025.

Growth in the cpap industry

  • 52% of ResMed’s fiscal-2025 revenue came from devices, according to the company’s business mix summary.[1]
  • $5.15 billion was ResMed’s total fiscal-2025 revenue, up 10% from fiscal 2024.[1]
  • $641.4 million was ResMed’s fiscal-2025 Residential Care Software revenue, up 10% year over year.[1]
  • $4.50 billion was ResMed’s fiscal-2025 Sleep and Breathing Health revenue, up from $4.10 billion in fiscal 2024.[1]
  • 13% was Fisher & Paykel Healthcare’s fiscal-2025 Homecare revenue growth, with Homecare revenue reaching $739.9 million.[20]
  • 36% of ResMed’s fiscal-2025 revenue came from masks and other products.[1]

Differentiation in the cpap industry

  • Two new obstructive-sleep-apnea masks were launched by Fisher & Paykel Healthcare during fiscal 2025.[20]
  • 36% of ResMed’s fiscal-2025 revenue was generated by masks and other products, the company’s second-largest reported business category.[1]
  • 52% of ResMed’s fiscal-2025 revenue was generated by devices, its largest reported business category.[1]
  • 40% was ResMed’s reported five-year total shareholder return as of June 30, 2025.[1]
  • 14% was Fisher & Paykel Healthcare’s fiscal-2025 full-year growth in obstructive-sleep-apnea mask revenue.[20]
  • 27% was ResMed’s reported three-year total shareholder return as of June 30, 2025.[1]

Mergers and acquisitions in the cpap industry

  • $113 million was Brightree’s approximate calendar-2015 net sales before ResMed acquired the company.[21]
  • $800 million in cash was paid by ResMed to acquire Brightree in April 2016.[21]
  • $300 million was the senior unsecured one-year term-loan facility associated with ResMed’s 2016 Brightree acquisition.[21]
  • One acquisition of Somnoware was completed by ResMed in 2022 to expand digital sleep and respiratory diagnostics software.[21]
  • $43 million was Brightree’s approximate calendar-2015 EBITDA before its acquisition by ResMed.[21]
  • $802 million was ResMed’s total cash purchase consideration for Brightree, according to a subsequent SEC filing.[21]

Strategic partnerships in the cpap industry

  • Two ResMed selling approaches—direct sales and independent distributors—were combined in Europe, Asia and other markets in fiscal 2025.[1]
  • One open-platform integration was created when ResMed acquired Somnoware, complementing AirView and Brightree in 2022.[21]
  • One additional ResMed distributor-selection criterion was a commitment to sleep-apnea treatment in fiscal 2025.[1]
  • One distributor-selection criterion used by ResMed was local knowledge of respiratory medicine in fiscal 2025.[1]
  • 23 ResMed country subsidiaries supported direct-sales operations across Europe, Asia and other markets in fiscal 2025.[1]

07 Statistics

People & Workforce

Workforce data highlights hiring cadence and turnover, alongside training and engagement metrics relevant to regulated quality work. ResMed reports approximately 13% employee turnover in fiscal 2026.

Hiring in the cpap industry

  • Fisher & Paykel Healthcare hired 343 permanent employees in New Zealand in fiscal 2026, representing a 9% hire rate.[22]
  • Fisher & Paykel Healthcare hired 1,237 permanent employees globally in fiscal 2025, representing a 17% hire rate.[22]
  • Women had a 9% permanent-employee hire rate at Fisher & Paykel Healthcare in fiscal 2026, compared with 9% for men.[22]
  • Fisher & Paykel Healthcare hired 132 permanent employees in Mexico in fiscal 2026, representing a 6% hire rate.[22]
  • Employees under 30 represented 508 permanent hires at Fisher & Paykel Healthcare in fiscal 2025, with a 29% hire rate.[22]

Employee retention in the cpap industry

  • ResMed’s average global employee turnover rate was approximately 12% in fiscal 2025.[1]
  • ResMed’s average global employee turnover rate was approximately 13% in fiscal 2026.[21]
  • Fisher & Paykel Healthcare recorded a 20% employee turnover rate in Mexico in fiscal 2025.[22]
  • ResMed’s average global employee turnover rate was approximately 18% in fiscal 2024.[1]
  • Fisher & Paykel Healthcare recorded a 10% employee turnover rate in New Zealand in fiscal 2025.[22]

Remote Work in the medical devices sector (sector benchmark)

  • Remote medical device and diagnostics employees worked an average of 41.5 hours per week in 2023, compared with 43 hours for office-based employees.[23]
  • Remote medical device and diagnostics professionals reported a median 4% pay increase in 2023, according to an industry salary survey.[23]
  • About 50% of medical device and diagnostics professionals worked fully remotely in 2023, based on 226 usable survey responses in the United States.[23]
  • Remote medical device and diagnostics professionals reported a median salary of $142,000 in 2023, according to an industry salary survey.[23]

Hybrid Work in the medical devices sector (sector benchmark)

  • Hybrid medical device professionals reported a median salary of $150,000 in 2026, compared with $140,000 for remote and $116,000 for in-office professionals.[23]
  • Hybrid medical device and diagnostics professionals represented about 40% of respondents in MD+DI’s 2023 salary survey, covering 226 usable responses.[23]
  • Hybrid medical device and diagnostics professionals reported a median 4% pay increase in 2023, according to an industry salary survey.[23]
  • Hybrid medical device and diagnostics professionals reported a median salary of $135,000 in 2023, according to an industry salary survey.[23]

Upskilling in the cpap industry

  • Fisher & Paykel Healthcare hosted lunch-and-learn sessions in fiscal 2025 to connect women engineering managers with role models and career-path guidance.[22]
  • Salaried employees at Fisher & Paykel Healthcare’s New Zealand, Mexico and international sales offices completed an average of 13.7 training hours in fiscal 2025.[24]

Employee Engagement in the medical devices sector (sector benchmark)

  • In medical devices, 91% of employees agreed they understood how their work contributed to company goals in benchmark data collected through June 2026.[25]
  • In medical devices, 73% of employees were engaged in benchmark data collected from July 2025 through June 2026, predominantly across Northern America, Oceania, Europe and Asia.[25]
  • Medical devices organizations had a median employee net promoter score of 14 in Culture Amp’s 2026 benchmark.[25]
  • In medical devices, 23% of employees disagreed that their total compensation was fair relative to similar roles at other companies in the 2026 benchmark.[25]

DEI in the cpap industry

  • Fisher & Paykel Healthcare employed 6 gender-diverse permanent employees in fiscal 2026.[22]
  • Employees aged 30 to 50 represented 59.6% of Fisher & Paykel Healthcare’s workforce in fiscal 2026.[22]
  • Employees over 50 represented 18.5% of Fisher & Paykel Healthcare’s workforce in fiscal 2026.[22]
  • Women held 37.5% of Fisher & Paykel Healthcare board seats in fiscal 2026.[22]
  • Women held 32.8% of Fisher & Paykel Healthcare management roles at the CEO-minus-two level in fiscal 2026.[22]

Change Management in the medical devices sector (sector benchmark)

  • Among post-market medical device companies surveyed in 2023, 37% cited resistance to change efforts as a challenge to improving quality management processes.[16]

08 Statistics

Customer & Sales

Sales inputs emphasize satisfaction, adherence predictors, and lead-generation performance for resupply. One used benchmark is a 17% landing-page conversion rate in a U.S. CPAP resupply campaign.

Customer experience in the cpap industry

  • 4.4 out of 5 was the average end-of-program satisfaction score among 74 users of a digital obstructive sleep-apnea program, United States, 2023.[26]
  • 62 users rated their digital obstructive sleep-apnea program experience positively with a score of 4 or 5, United States, 2023.[26]
  • Patient satisfaction with titration was associated with CPAP acceptance at an odds ratio of 12.83 in a Chinese patient study, 2017–2018.[18]
  • 73% of users who rated their digital obstructive sleep-apnea program experience positively were adherent, United States, 2023.[26]
  • 58% of respondents in a digital obstructive sleep-apnea program rated their program satisfaction 5 out of 5 at study end, United States, 2023.[26]

Customer retention in the cpap industry

  • Average CPAP use during the first two weeks predicted six-month adherence at an odds ratio of 1.88 per additional unit in a Chinese study, 2017–2018.[18]
  • Approximately 50% of CPAP patients use therapy too infrequently or stop completely within a few years of starting, according to a 2024 report summarizing CPAP adherence research.[27]
  • One-third of CPAP treatment acceptors had poor adherence at six months in a Chinese study, 2017–2018.[18]
  • Global problems associated with CPAP use predicted lower six-month adherence at an odds ratio of 0.82 in a Chinese study, 2017–2018.[18]
  • Two-thirds of CPAP treatment acceptors reported good adherence six months after starting therapy in a Chinese study, 2017–2018.[18]

Customer acquisition in the cpap industry

  • 178,493 Google impressions were delivered in a United States CPAP resupply campaign.[28]
  • 1,381 total leads came from Google in a United States CPAP resupply campaign.[28]
  • 114,930 Facebook impressions were delivered in a United States CPAP resupply campaign.[28]
  • 17% was the landing-page conversion rate in a United States CPAP resupply campaign.[28]
  • 277 new CPAP resupply patients were generated by a United States specialty medical-equipment campaign over five months.[28]

Customer loyalty in the cpap industry

  • 10.4% was Fisher & Paykel Healthcare’s share of tracked CPAP-brand searches worldwide in September 2026.[29]
  • 0.148 was the standardized coefficient linking after-sales service with customer loyalty in a CPAP purchasing study, Malaysia, 2022.[19]
  • 10.4% was Philips Respironics’ share of tracked CPAP-brand searches worldwide in September 2026.[29]
  • 0.083 was the standardized coefficient linking after-sales service with customer retention in a CPAP purchasing study, Malaysia, 2022.[19]
  • 77.1% was ResMed’s share of tracked CPAP-brand searches worldwide in September 2026.[29]

Lead generation in the cpap industry

  • 277 new CPAP resupply patients resulted from the reported United States lead-generation campaign.[28]
  • 17% was the landing-page conversion rate for a United States CPAP resupply campaign.[28]
  • 496 Facebook leads were generated for a United States CPAP resupply provider in the reported campaign.[28]
  • 1,381 Google leads were generated for a United States CPAP resupply provider in the reported campaign.[28]
  • $3.13 was the average Facebook cost per lead for a United States CPAP resupply campaign.[28]

09 Statistics

Marketing & Brand

Brand tracking aligns search share with reported ad impressions and campaign conversions. ResMed’s tracked worldwide CPAP-brand search share was 77.1% in September 2026.

Marketing in the cpap industry

  • 277 new CPAP resupply patients were attributed to a five-month marketing campaign for a United States medical-equipment provider.[28]
  • 178,493 Google ad impressions were recorded in a United States CPAP resupply marketing campaign.[28]
  • 114,930 Facebook ad impressions were recorded in a United States CPAP resupply marketing campaign.[28]

Digital marketing in the cpap industry

  • 201,000 estimated monthly branded searches were recorded for ResMed worldwide in September 2026.[29]
  • 17% was the landing-page conversion rate in a United States CPAP digital-marketing campaign.[28]
  • $3.13 was the average Facebook cost per lead in a United States CPAP digital-marketing campaign.[28]
  • 27,100 estimated monthly branded searches were recorded for Philips Respironics worldwide in September 2026.[29]
  • 27,100 estimated monthly branded searches were recorded for Fisher & Paykel Healthcare worldwide in September 2026.[29]

Branding in the cpap industry

  • 78.8% was ResMed’s peak share of tracked worldwide CPAP-brand searches during the 11 months ending September 2026.[29]
  • 12.6% was Philips Respironics’ peak share of tracked worldwide CPAP-brand searches during the 11 months ending September 2026.[29]
  • 0.73% was BMC Medical’s worldwide share of tracked CPAP-brand searches in September 2026.[29]
  • 1.4% was Löwenstein Medical’s worldwide share of tracked CPAP-brand searches in September 2026.[29]
  • 77.1% was ResMed’s worldwide share of tracked CPAP-brand searches in September 2026.[29]

Influencer Marketing in the medical devices sector (sector benchmark)

  • 50% of healthcare and pharmaceutical marketers had dedicated, growing budgets for creator or influencer marketing in 2026.[30]
  • 10% of healthcare and pharmaceutical marketers reported that they did not invest in creator or influencer marketing in 2026.[30]
  • 8% of healthcare and pharmaceutical marketers had dedicated but shrinking budgets for creator or influencer marketing in 2026.[30]
  • 1.07% was the average engagement rate for health-industry influencer posts globally in 2023, across the platforms measured by Sprout Social.[31]
  • 29% of healthcare and pharmaceutical marketers had dedicated but flat budgets for creator or influencer marketing in 2026.[30]

10 Statistics

Operations & Execution

Operations in CPAP are dominated by remediation execution and inventory/manufacturing capacity reporting. Philips reported 99% of registered affected CPAP and BiPAP devices remediated by December 2025.

Process optimization in the cpap industry

  • 65,000 Philips Respironics devices remained expected to be remediated worldwide at December 31, 2025.[32]
  • ResMed operated principal manufacturing facilities in Australia, China, Malaysia, Singapore, France and the United States as of June 30, 2025.[33]
  • ResMed reported 4,590 employees in cost-of-sales activities, including warehousing and manufacturing, at June 30, 2026.[1]
  • Philips incurred EUR 112 million in Respironics field-action running remediation costs during 2025.[32]
  • 99% of registered Philips CPAP and BiPAP devices affected by the 2021 recall had been remediated globally by December 2025.[32]

Operational efficiency in the cpap industry

  • Fisher & Paykel Healthcare’s company-wide gross margin increased to 62.9% in the 2025 financial year.[22]
  • ResMed’s sleep and breathing health revenue reached $4.978 billion in fiscal 2026.[1]
  • ResMed’s gross margin increased to 61.1% in fiscal 2026 from 59.4% in fiscal 2025.[1]
  • ResMed’s sleep and breathing health cost of sales was $1.953 billion in fiscal 2026.[1]
  • Fisher & Paykel Healthcare’s homecare revenue increased 13% in the 2025 financial year.[20]

Quality management in the cpap industry

  • Philips completed field-safety closures in 31 countries for the Respironics recall by December 2025.[32]
  • Philips incurred EUR 112 million in field-action running remediation costs during 2025, including testing, external advisory and regulatory-response costs.[32]
  • Philips’ Respironics field-action provision balance fell to EUR 36 million at December 31, 2025, from EUR 130 million a year earlier.[21]
  • Philips completed all steps required by the U.S. recall remediation plan for June 2021 sleep-therapy devices by July 6, 2026.[34]
  • Approximately 65,000 Philips Respironics devices remained to be remediated worldwide at December 31, 2025.[32]

Supply chain in the cpap industry

  • ResMed’s raw-material inventories totaled $367.3 million at June 30, 2025.[33]
  • ResMed held $927.7 million in inventories at June 30, 2025, including $557.9 million of finished goods.[33]
  • ResMed’s principal manufacturing network included facilities in Australia, China, Malaysia, Singapore, France and the United States at June 30, 2025.[33]
  • Philips reported EUR 112 million of 2025 Respironics remediation running costs, including material, labor and logistics costs.[32]
  • ResMed’s finished-goods inventories increased from $464.0 million in 2024 to $557.9 million in 2025.[33]

Outsourcing / Offshoring in the medical devices sector (sector benchmark)

  • 335 U.S. medical device contract manufacturers were identified in 2022, up from 314 in the prior registry.[35]
  • $26.3 billion was the U.S. medtech CDMO market in 2023, after 12.9% growth from 2022.[35]
  • 11.4% was the year-over-year growth rate of the global medtech outsourcing market in 2023.[35]
  • More than half of 59 global medtech CDMO transactions in 2023 had cross-border characteristics.[35]
  • $18.5 billion was the European medtech CDMO market in 2023.[35]

11 Statistics

Finance & Pricing

Pricing signals include cash-price ranges for U.S. purchases and noted reimbursement mechanics under Medicare. Reported cash prices for CPAP machines without insurance range from $300–$1,500 in 2026.

Pricing strategy in the cpap industry

  • $300–$1,500 is the reported U.S. cash-price range for CPAP machines without insurance in 2026.[36]
  • $200–$900 is the reported U.S. price range for certified pre-owned or refurbished CPAP devices in 2026.[36]
  • $1,000 is the approximate average U.S. price for a new CPAP or APAP device in 2026.[36]
  • $1,700–$3,000 is the typical U.S. price range for a BiPAP machine in 2026.[36]
  • $400–$1,600 is the typical U.S. price range for new CPAP or APAP machines in 2026.[36]

Cost reduction in the cpap industry

  • ResMed’s manufacturing and warehousing workforce increased to approximately 4,590 employees in fiscal 2026.[1]
  • Philips’ adjusted EBITA margin increased to 12.3% in 2025 from 11.5% in 2024, partly reflecting productivity actions.[32]
  • Fisher & Paykel Healthcare’s gross margin improved by 129 basis points in the 2025 financial year.[22]
  • ResMed’s gross margin improved by 170 basis points to 61.1% in fiscal 2026 from 59.4% in fiscal 2025.[1]
  • Philips’ Respironics field-action provision balance decreased by EUR 94 million during 2025, from EUR 130 million to EUR 36 million.[21]

Profitability in the cpap industry

  • ResMed’s sleep and breathing health revenue was $4.978 billion in fiscal 2026.[1]
  • Fisher & Paykel Healthcare’s homecare revenue reached $739.9 million in the 2025 financial year.[20]
  • ResMed’s non-GAAP operating margin was 35.2% in the fourth quarter of fiscal 2026.[1]
  • Fisher & Paykel Healthcare’s company-wide gross margin was 62.9% in the 2025 financial year.[22]
  • ResMed’s fiscal 2026 revenue increased 10% to approximately $5.7 billion.[1]

Financial planning in the cpap industry

  • Fisher & Paykel Healthcare’s research and development expense was $116.8 million in the 2025 financial year.[22]
  • ResMed incurred $22 million in restructuring-related charges for workforce planning activities in fiscal 2026.[1]
  • ResMed allocated $378.3 million, or 6.7% of net revenue, to research and development in fiscal 2026.[1]
  • ResMed allocated $1.120 billion, or 19.8% of net revenue, to selling, general and administrative expenses in fiscal 2026.[1]
  • Fisher & Paykel Healthcare invested $226.9 million in research and development during the 2025 financial year.[20]

12 Statistics

Product & Service

Product and service activity centers on FDA-cleared features, connected-use outcomes, and replacement guidance. ResMed launched Smart Comfort in 2026.

Product development in the cpap industry

  • More than 50 internal quality audits were conducted annually by ResMed across its business in fiscal 2023.[37]
  • 4.6 million or more diagnostic tests had been processed in ResMed’s cloud as of March 31, 2026.[1]
  • 2026 was the launch year for Smart Comfort, an FDA-cleared AI-enabled device that recommends personalized comfort settings for people starting CPAP therapy.[1]
  • 17% of ResMed employees were devoted to research and development in fiscal 2023.[37]
  • $287.6 million was invested in research and development by ResMed in fiscal 2023, equal to approximately 7% of net revenue.[37]

Product lifecycle in the cpap industry

  • 5% of CPAP devices in the government program were condemned within their first 3 years.[19]
  • 5 years is ResMed’s recommended replacement interval for a CPAP device in its U.S. replacement guidance.[38]
  • 12.4 years was the median age at end of life for CPAP devices in a government-funded equipment program.[19]
  • 13% of CPAP devices in the government program were condemned within their first 5 years.[19]
  • 5 to 7 years is the typical stated lifespan of a CPAP device, according to ResMed’s U.S. replacement guidance.[38]

After-sales in the cpap industry

  • 163 minutes was the mean total consultation time per patient in the telemonitoring group in a one-year CPAP trial.[18]
  • 25% of telemonitoring-group patients discontinued CPAP by 12 months in a randomized trial using ResMed AirView.[19]
  • 31 countries had completed field-safety closures for Philips’ recalled CPAP and BiPAP devices by December 2025.[21]
  • 178 minutes was the mean total consultation time per patient in the usual-care group in a one-year CPAP trial.[18]
  • 34% of usual-care patients discontinued CPAP by 12 months in the same randomized trial.[19]

Value proposition in the cpap industry

  • 53.5% was the Medicare-adherence rate for the usual-care group in the Tele-OSA trial.[18]
  • 5.9 hours was the average nightly PAP use among patients using both myAir and AirView in a ResMed study.[14]
  • 160 million or more individual patient accounts were supported by ResMed’s residential-care software solutions in fiscal 2025.[21]
  • 28 billion or more nights of sleep data underpinned ResMed’s digital ecosystem in fiscal 2026.[1]
  • 73.2% was the Medicare-adherence rate for the combined telemedicine-education and telemonitoring group in the Tele-OSA trial.[18]

13 Statistics

Sustainability & Ethics

Sustainability reporting is present alongside compliance training metrics. ResMed reports 85% of non-hazardous waste recycled in fiscal 2025 globally.

Sustainability in the cpap industry

  • 85% of ResMed’s non-hazardous waste was recycled in fiscal 2025 globally.[39]
  • 247,667 gigajoules of energy were consumed by ResMed in fiscal 2025 globally.[39]
  • 27,530 metric tons of Scope 1 and Scope 2 greenhouse-gas emissions were reported by ResMed in fiscal 2025 globally.[39]
  • 57 metric tons of paper were consumed by ResMed in fiscal 2025 globally.[39]
  • 209,791 kiloliters of water were withdrawn by ResMed in fiscal 2025 globally.[39]

ESG in the cpap industry

  • 8 metric tons of used paper were recycled by ResMed in fiscal 2025 globally.[39]
  • 3,957 metric tons of Scope 1 emissions were reported by ResMed in fiscal 2025 globally.[39]
  • 1,068 metric tons of non-hazardous waste were sent to landfill by ResMed in fiscal 2025 globally.[39]
  • 6,140 metric tons of non-hazardous recycling waste were recorded by ResMed in fiscal 2025 globally.[39]
  • 23,573 metric tons of Scope 2 emissions were reported by ResMed in fiscal 2025 globally.[39]

Ethics in the cpap industry

  • 89.44% of ResMed employees received anti-bribery, anti-corruption, compliance and code-of-conduct training in fiscal 2025 globally.[39]
  • 1 incident of non-compliance concerning product and service information and labeling was reported by ResMed in fiscal 2024.[39]
  • 91.11% of ResMed’s new employees received code-of-business-conduct and ethics training in fiscal 2025 globally.[39]

CSR in the cpap industry

  • 19 employee-driven resource groups operated at ResMed in fiscal 2025 globally.[21]
  • 15.23% of ResMed’s workforce consisted of contingent workers on a headcount basis in fiscal 2025 globally.[39]
  • 10,595 full-time-equivalent employees were reported by ResMed in fiscal 2025 globally.[39]
  • 12% was ResMed’s average global employee turnover rate in fiscal 2025.[21]
  • 53.12% of ResMed employees measured on an FTE basis were women in fiscal 2025 globally.[39]

Circular economy in the cpap industry

  • 69% of ResMed’s non-hazardous waste was recycled in fiscal 2023 globally.[39]
  • 94.45 metric tons of hazardous waste were recycled by ResMed in fiscal 2023 globally.[39]
  • 5,365 metric tons of non-hazardous recycling waste were recorded by ResMed in fiscal 2023 globally.[39]
  • 5,578 metric tons of non-hazardous recycling waste were recorded by ResMed in fiscal 2024 globally.[39]
  • 75% of ResMed’s non-hazardous waste was recycled in fiscal 2024 globally.[39]

Carbon footprint in the cpap industry

  • 28,391 metric tons of total greenhouse-gas emissions were reported by ResMed in fiscal 2023 globally.[39]
  • 4,236 metric tons of Scope 1 emissions were reported by ResMed in fiscal 2024 globally.[39]
  • 28,658 metric tons of total greenhouse-gas emissions were reported by ResMed in fiscal 2024 globally.[39]
  • 27,530 metric tons of total greenhouse-gas emissions were reported by ResMed in fiscal 2025 globally.[39]
  • 4,453 metric tons of Scope 1 emissions were reported by ResMed in fiscal 2023 globally.[39]

15 Statistics

Globalization & Expansion

Expansion metrics tie regional revenue to global reach through direct and distributor channels. ResMed reports sleep and breathing health revenue of $1.51 billion from Europe, Asia and other markets in fiscal 2025.

Globalization in the cpap industry

  • $1.51 billion was ResMed’s fiscal-2025 Sleep and Breathing Health revenue from Europe, Asia and other markets.[1]
  • $3.00 billion was ResMed’s fiscal-2025 Sleep and Breathing Health revenue from the United States, Canada and Latin America.[1]
  • 9% was the fiscal-2025 year-over-year increase in ResMed Sleep and Breathing Health revenue from Europe, Asia and other markets.[1]
  • 10% was ResMed’s fiscal-2025 global Sleep and Breathing Health revenue growth, reaching $4.50 billion.[1]
  • 140+ countries were served by ResMed in fiscal 2025, covering sleep-apnea and other out-of-hospital health products and services.[1]

Stakeholder management in the cpap industry

  • More than 30 million ResMed cloud-connectable devices were in the company’s connected-health ecosystem in fiscal 2025.[1]
  • 6% of ResMed’s fiscal-2025 revenue was invested in research and development, according to the company’s corporate summary.[1]
  • More than 23 billion nights of medical sleep and respiratory data were represented in ResMed’s fiscal-2025 corporate summary.[1]
  • 4,240 ResMed employees were engaged in cost-of-sales activities, including warehousing and manufacturing, as of June 30, 2025.[1]
  • 10,600 employees worked at ResMed as of June 30, 2025, including approximately 1,990 in research and development.[1]

Distribution channels in the cpap industry

  • One principal U.S. route to market for ResMed products was through home-medical-equipment providers that then sold products to patients in fiscal 2025.[1]
  • Two main channel types—direct sales and independent distributors—were used by ResMed in Europe, Asia and other markets in fiscal 2025.[1]
  • 23 wholly owned ResMed subsidiaries were listed across Europe, Asia and other markets in fiscal 2025.[1]
  • More than 140 countries were reached by ResMed through distributors and direct sales staff in fiscal 2025.[1]

Key questions about the Cpap Industry

How large is the global CPAP devices market in 2026?
The global CPAP devices market is estimated at $1.97 billion in 2026.
What is the expected market growth for CPAP devices from 2026 to 2035?
The market is forecast to grow at a 4.88% compound annual growth rate from 2026 to 2035.
Which companies lead the cpap industry?
Fisher & Paykel Healthcare leads Gitnux's 2026 cpap ranking with an Overall score of 9.9, with 13% Homecare revenue growth to $739.9 million. ResMed is the highest-ranked connected therapy software provider at 9.5, with $5.15 billion fiscal-2025 total revenue, up 10% year over year.
What technology shift is changing CPAP therapy delivery and measurement?
Growth is supported by auto-adjusting devices and cloud-connected adherence tools, and connected therapy is becoming standard.
How is the CPAP market structured by region?
North America held 47.0% of global CPAP-device revenue in 2025, while Europe represented 24.0% in the same year.
What compliance and payment requirements shape CPAP adoption in the U.S.?
U.S. Medicare coverage requires a qualifying obstructive-sleep-apnea diagnosis, a 12-week trial, and documented benefit; CMS reported a 12.5% improper-payment rate for CPAP in 2024.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Catherine Wu. (2026, February 13). Cpap Industry Statistics. Gitnux. https://gitnux.org/cpap-industry-statistics
MLA
Catherine Wu. "Cpap Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/cpap-industry-statistics.
Chicago
Catherine Wu. 2026. "Cpap Industry Statistics." Gitnux. https://gitnux.org/cpap-industry-statistics.

Sources & references

56 sources cited across this report

  1. investor.resmed.com
  2. bcg.com
  3. nsf.org
  4. mastercontrol.com
  5. veeva.com
  6. monitor-industrial-ecosystems.ec.europa.eu
  7. pages.awscloud.com
  8. www-statista-com.libproxy.pcc.edu
  9. modeln.com
  10. plm.automation.siemens.com
  11. eseye.com
  12. ashb.com
  13. journal.chestnet.org
  14. s24.q4cdn.com
  15. sana-suisse-med.ch
  16. blog.greenlight.guru
  17. distillersr.com
  18. pubmed.ncbi.nlm.nih.gov
  19. pmc.ncbi.nlm.nih.gov
  20. fphcare.com
  21. sec.gov
  22. financialfilings.com
  23. mddionline.com
  24. device.report
  25. cultureamp.com
  26. frontiersin.org
  27. time.com
  28. somnowellmarketing.com
  29. gobrandwave.com
  30. brand-news.it
  31. media.sproutsocial.com
  32. results.philips.com
  33. materials.proxyvote.com
  34. usa.philips.com
  35. alirahealth.com
  36. sleepapnea.org
  37. d1io3yog0oux5.cloudfront.net
  38. resmed.com
  39. document.resmed.com
  40. fda.gov
  41. accessdata.fda.gov
  42. greenlight.guru
  43. cognition.us
  44. runsafesecurity.com
  45. dennemeyer.com
  46. deloitte.com
  47. mdic.org
  48. 2bridge.partners
  49. datamintelligence.com
  50. emergenresearch.com
  51. medicare.gov
  52. cms.gov
  53. reacthealth.com
  54. loewensteinmedical.com
  55. wellell.com
  56. newsroom.resmed.com